지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Several new antithrombotic drugs have been developed and approved to use in clinical practice recently. Dabigatran, a direct thrombin inhibitor, and rivaroxaban, a factor Xa inhibitor, have been approved in many countries including Korea to prevent stroke in patient with atrial fibrillation. Apixaban, another factor Xa inhibitor, showed good results in clinical trial and is waiting for approval for clinical use. New antiplatelet agent, terutroban, selective thromboxane A2 receptor inhibitor, failed to prove the efficacy over the aspirin in secondary stroke prevention. Vorapaxar, a new antiplatelet agent that inhibits thrombin through PAR-1 antagonism, showed a high incidence of intracranial hemorrhage in patient with a history of stroke.
목차
등록된 정보가 없습니다.
참고문헌 (21)
참고문헌 신청
/ / Bayer Schering Pharma. Xarelto® summary of product characteristics? EU
/ 2011 / Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation
Blech S / 2008 / The metabolism and disposition of the oral direct thrombin inhibitor., dabigatran., in humans / Drug Metab Dispos 36 : 386 ~ 399
Connolly SJ / 2009 / Dabigatran versus warfarin in patients with atrial fibrillation / N Engl J Med 361 : 1139 ~ 1151
Eriksson BI / 2004 / Dose escalating safety study of a new oral direct thrombin inhibitor., dabigatran etexilate., in patients undergoing total hip replacement: BISTRO I / J
/ 2011 / Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation
Blech S / 2008 / The metabolism and disposition of the oral direct thrombin inhibitor., dabigatran., in humans / Drug Metab Dispos 36 : 386 ~ 399
Connolly SJ / 2009 / Dabigatran versus warfarin in patients with atrial fibrillation / N Engl J Med 361 : 1139 ~ 1151
Eriksson BI / 2004 / Dose escalating safety study of a new oral direct thrombin inhibitor., dabigatran etexilate., in patients undergoing total hip replacement: BISTRO I / J
이 논문의 저자 정보
최근 본 자료
댓글(0)
0